Akebia Therapeutics (AKBA) Total Debt Growth (1y) (2019 - 2026)
Akebia Therapeutics (AKBA) Total Debt Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -11.90% |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -0.14% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 37.52% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -10.56% |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -9.53% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -13.33% |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | 5.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.11% |
| Dec 31, 2025 | 24.70% |
| Sep 30, 2025 | 24.21% |
| Jun 30, 2025 | 23.75% |
| Mar 31, 2025 | 54.29% |
| Dec 31, 2024 | 11.56% |
| Sep 30, 2024 | -9.99% |
| Jun 30, 2024 | -10.49% |
| Mar 31, 2024 | -40.06% |
| Dec 31, 2023 | -47.51% |
| Sep 30, 2023 | -67.69% |
| Jun 30, 2023 | -78.36% |
| Mar 31, 2023 | -48.60% |
| Dec 31, 2022 | -32.26% |
| Sep 30, 2022 | 35.65% |
| Jun 30, 2022 | 102.56% |
| Mar 31, 2022 | 1.28% |
| Dec 31, 2021 | 1.21% |
| Sep 30, 2021 | 26.92% |
| Jun 30, 2021 | 26.96% |